

**Table 36: Clinical evidence profile: Comparison 7. Oral ciprofloxacin + inhaled colistin versus inhaled tobramycin for acute infection with *P aeruginosa***

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Oral ciprofloxacin + inhaled colistin	inhaled tobramycin	Relative (95% CI)	Absolute		
<b>Adverse events: severe cough (follow-up 3 months)</b>												
1 (Proe smans 2013)	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	very serious <sup>2</sup>	none	0/29 (0%)	1/29 (3.4%)	RR 0.33 (0.01 to 7.86)	23 fewer per 1000 (from 34 fewer to 237 more)	VERY LOW	IMPORTANT

Abbreviations: CI: confidence interval; RR: risk ratio

1 The quality of the evidence was downgraded by 1 due to no blinding. Blinding was not possible due to route of administration (oral versus inhaled).

2 The quality of the evidence was downgraded by 2 due to very serious imprecision as 95% CI crossed 2 default MIDs.